Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
LIGNOSPAN STANDARD vs ISOCAINE HYDROCHLORIDE W/ LEVONORDEFRIN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Lidocaine, the active ingredient, inhibits voltage-gated sodium channels, blocking the initiation and conduction of nerve impulses, leading to local anesthesia.
Isocaine hydrochloride (mepivacaine) is an amino amide local anesthetic that blocks sodium ion channels in nerve cell membranes, thereby inhibiting the initiation and conduction of nerve impulses. Levonordefrin is a vasoconstrictor that acts on alpha-adrenergic receptors to cause local vasoconstriction, prolonging the anesthetic effect.
Local or regional anesthesia for dental procedures,Local infiltration anesthesia,Nerve block anesthesia
Local anesthesia for dental procedures,Local anesthesia for surgical procedures,Infiltration anesthesia,Nerve block anesthesia
2% lidocaine with 1:100,000 epinephrine: 1-5 m L (20-100 mg lidocaine) locally infiltrated; max 7 mg/kg lidocaine (up to 500 mg) per procedure. For nerve block: 1-30 m L depending on site. Epinephrine max 0.2 mg (20 m L of 1:100,000 solution) in healthy adults.
Adult dental infiltration or nerve block: 1-2 m L of 2% solution (20 mg/m L isocaine hydrochloride with levonordefrin 1:20,000) administered subcutaneously; maximum single dose 5 m L (100 mg isocaine hydrochloride); maximum total dose 7 m L per appointment.
Terminal elimination half-life is approximately 1.5–2 hours in adults. Prolonged in hepatic impairment or heart failure.
Terminal elimination half-life is approximately 2.1 hours; clinically, accumulation may occur with repeated doses in renal impairment.
Primarily metabolized by CYP3A4 to monoethylglycinexylidide and glycinexylidide; also undergoes deethylation and hydrolysis.
Isocaine hydrochloride (mepivacaine) is primarily metabolized in the liver by cytochrome P450 enzymes, mainly CYP1A2 and CYP3A4, to inactive metabolites. Levonordefrin is metabolized by monoamine oxidase (MAO) and catechol-O-methyltransferase (COMT).
Primarily hepatic metabolism; <10% excreted unchanged in urine. Biliary/fecal excretion is minimal.
Renal excretion of metabolites, primarily 4-hydroxy-2,6-dimethylaniline glucuronide and sulfate conjugates; less than 5% excreted unchanged in urine.
Approximately 65% bound to plasma proteins, primarily alpha-1-acid glycoprotein (AAG) and albumin.
Approximately 60% bound to plasma proteins, primarily alpha-1-acid glycoprotein.
Volume of distribution (Vd) is approximately 0.6–1.0 L/kg. Reflects extensive tissue distribution.
Vd is approximately 1.0 L/kg; distribution is rapid and extensive, indicating high tissue uptake.
Bioavailability: ~100% for intravenous; approximately 85–90% for intramuscular; negligible after oral administration due to extensive first-pass metabolism.
Intravenous: 100%; Intramuscular: ~100%; Subcutaneous: ~100%; Oral: 10-30% due to first-pass metabolism.
No dose adjustment required for lidocaine; however, caution in severe renal impairment due to potential accumulation of metabolites. GFR <30 m L/min: monitor for toxicity.
No specific dosing adjustment required for mild to moderate renal impairment; for severe impairment (GFR <30 m L/min), consider reducing dose by 25-50% due to risk of methemoglobinemia; monitor methemoglobin levels.
Child-Pugh A: no adjustment. Child-Pugh B: reduce dose by 50%. Child-Pugh C: contraindicated or use with extreme caution; reduce dose by 75% and monitor levels.
Child-Pugh Class A: No adjustment. Class B: Reduce dose by 50%; maximum single dose 50 mg. Class C: Avoid use or use with extreme caution; alternative agent recommended.
Lidocaine 2% with epinephrine: 0.5-2.5 mg/kg per dose (max 4.5 mg/kg lidocaine, epinephrine max 0.01 m L/kg of 1:100,000 solution). For infiltration: 1-2 m L/kg of 0.5-1% solution (without epinephrine in young infants).
Weight-based dose: 1-2 mg/kg isocaine hydrochloride per injection, maximum 4.4 mg/kg total; not to exceed adult doses. For dental procedures, typical dose 0.5-1 m L per injection site depending on weight.
Reduce initial doses due to decreased hepatic clearance and increased sensitivity; use lowest effective dose. Maximum single dose: 200 mg lidocaine (without epinephrine) or 300 mg (with epinephrine). Monitor for CNS and cardiac toxicity.
Elderly patients (≥65 years): Reduced dose due to decreased hepatic metabolism; initial dose 50% of adult dose; maximum single dose 50 mg; monitor for CNS and cardiovascular side effects.
Not available.
Intravascular injection of local anesthetics can cause sudden cardiac arrest, especially in children. Resuscitative equipment and personnel trained in advanced cardiac life support must be immediately available.
Excessive blood levels may cause CNS and cardiovascular toxicity; use lowest effective dose; caution in patients with hepatic disease, cardiac disease, or epilepsy; monitor for signs of systemic toxicity.
Risk of systemic toxicity from inadvertent intravascular injection,Caution in patients with hepatic impairment due to reduced metabolism,Caution in patients with cardiovascular disease due to vasoconstrictor effects of levonordefrin,Avoid use in patients with severe hypertension or thyrotoxicosis,Use lowest effective dose to minimize risk of adverse effects
Hypersensitivity to lidocaine or amide-type anesthetics; severe hypotension; myasthenia gravis; severe heart block; untreated hypovolemia.
Hypersensitivity to mepivacaine, levonordefrin, or other amide-type local anesthetics,Severe hypotension or cardiogenic shock,Thromboembolic disease,Use of MAO inhibitors or tricyclic antidepressants within 14 days,Severe hypertension or thyrotoxicosis
No significant food interactions. Avoid citrus fruits or acidic foods immediately after injection as they may irritate the injection site.
No significant food interactions. Avoid alcohol before and after dental procedure to reduce risk of bleeding and enhanced sedation.
Lignospan standard contains lidocaine and epinephrine. Lidocaine crosses the placenta and is classified as FDA pregnancy category B; no evidence of teratogenicity in animal studies, but human data are limited. Epinephrine may cause uterine vasoconstriction and reduce placental blood flow, especially in high doses or with inadvertent intravascular injection. During the first trimester, risk is minimal with standard doses. In the second and third trimesters, no known increased risk of malformations. During labor and delivery, high doses or repeated administration may lead to fetal bradycardia or neonatal depression due to lidocaine accumulation.
In the first trimester, no well-controlled studies in humans; animal studies insufficient. In second and third trimesters, lidocaine (component) crosses placenta with fetal serum levels ~50% maternal; no major teratogenic risk in typical doses. Levonordefrin is a vasoconstrictor; risk of uteroplacental insufficiency at high doses. Avoid during first trimester if possible.
Lidocaine is excreted into breast milk in small quantities, with an estimated M/P ratio of approximately 0.4. The relative infant dose via breast milk is less than 4% of the maternal weight-adjusted dose and is considered compatible with breastfeeding. Epinephrine is not orally bioavailable. Lignospan standard is safe for use during lactation with appropriate dosing.
Lidocaine excreted into breast milk in small amounts (<1% maternal dose); M/P ratio ~0.3-0.6. Levonordefrin likely minimal excretion. Compatible with breastfeeding with caution; avoid large doses.
Pregnancy may increase lidocaine clearance due to increased hepatic blood flow and volume of distribution, but no dose adjustment is recommended for standard local anesthetic doses. However, reduced doses may be necessary in patients with preeclampsia or impaired placental perfusion. Epinephrine dose should be minimized to avoid uterine vasoconstriction.
No routine dose adjustments required for lidocaine in pregnancy. However, increased plasma volume and cardiac output may reduce peak concentrations; consider using lowest effective dose and avoiding excessive levonordefrin to prevent uterine vasoconstriction. Use with caution in preeclampsia or hypertension.
Lignospan Standard is a 2% lidocaine with 1:100,000 epinephrine dental anesthetic. Aspiration before injection is critical to prevent intravascular administration. Avoid use in patients with severe heart block, uncontrolled hypertension, or hyperthyroidism due to epinephrine. Maximum dose: 4.4 mg/kg lidocaine (0.7 mg/kg epinephrine). Use with caution in patients on MAOIs, tricyclic antidepressants, or beta-blockers due to potential hypertensive crisis or reduced heart rate.
ISOCAINE HYDROCHLORIDE W/ LEVONORDEFRIN is a dental anesthetic combination. Levonordefrin is a vasoconstrictor that prolongs anesthetic action. Avoid intravascular injection to prevent systemic toxicity. Use caution in patients with cardiovascular disease, hypertension, or hyperthyroidism due to levonordefrin. Maximum dose: 5.4 mg/kg of isocaine base. Contraindicated in patients with sulfite allergy (contains sodium metabisulfite).
Avoid eating or drinking until numbness wears off to prevent accidental biting of tongue or cheek.,Do not operate machinery or drive for at least 30 minutes after injection.,Apply ice to injection site if swelling occurs; report persistent pain or infection.,Inform your dentist of all medications, especially those for depression, high blood pressure, or heart problems.
You will receive an injection for dental numbness lasting about 1-3 hours.,Avoid chewing on the numbed area to prevent accidental injury.,Do not eat or drink hot liquids until sensation fully returns.,Report any signs of allergic reaction (rash, swelling, difficulty breathing) immediately.,Inform your dentist if you have heart disease, high blood pressure, or thyroid problems.
No interactions on record
"Levonordefrin, a vasoconstrictor with beta-agonist activity, may counteract the beta-blocking effects of pindolol, leading to unopposed alpha-adrenergic stimulation and potential hypertensive crisis. Additionally, pindolol's intrinsic sympathomimetic activity (ISA) may interact with levonordefrin, increasing the risk of cardiac arrhythmias and AV block due to conflicting adrenergic signaling. Clinically, this can result in severe hypertension, bradycardia, or heart block, especially in patients with underlying cardiovascular disease."
"Mianserin, a tetracyclic antidepressant with potent alpha-2-adrenergic receptor antagonism, can reduce the vasopressor response to Levonordefrin, a direct-acting alpha-1 adrenergic agonist. This interaction occurs because Mianserin blocks presynaptic alpha-2 receptors, leading to increased norepinephrine release and potential receptor desensitization, as well as possible competitive antagonism at the alpha-1 receptor. Clinically, this may result in diminished efficacy of Levonordefrin when used as a local vasoconstrictor during dental or surgical procedures, potentially leading to inadequate hemostasis or reduced local anesthesia duration."
"Levonordefrin, a sympathomimetic amine with alpha- and beta-adrenergic agonist activity, can enhance the negative dromotropic effect of arotinolol, a non-selective beta-blocker with intrinsic sympathomimetic activity. This results in additive depression of atrioventricular (AV) nodal conduction, potentially leading to prolonged PR interval, second- or third-degree AV block, and symptomatic bradycardia. Clinically, patients may present with dizziness, syncope, or hemodynamic instability, particularly in those with pre-existing conduction abnormalities."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about LIGNOSPAN STANDARD vs ISOCAINE HYDROCHLORIDE W/ LEVONORDEFRIN, answered by our medical review team.
LIGNOSPAN STANDARD is a Local Anesthetic with Vasoconstrictor that works by Lidocaine, the active ingredient, inhibits voltage-gated sodium channels, blocking the initiation and conduction of nerve impulses, leading to local anesthesia.. ISOCAINE HYDROCHLORIDE W/ LEVONORDEFRIN is a Local Anesthetic with Vasoconstrictor that works by Isocaine hydrochloride (mepivacaine) is an amino amide local anesthetic that blocks sodium ion channels in nerve cell membranes, thereby inhibiting the initiation and conduction of nerve impulses. Levonordefrin is a vasoconstrictor that acts on alpha-adrenergic receptors to cause local vasoconstriction, prolonging the anesthetic effect.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between LIGNOSPAN STANDARD and ISOCAINE HYDROCHLORIDE W/ LEVONORDEFRIN depend on the specific clinical indication. These are both Local Anesthetic with Vasoconstrictor agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of LIGNOSPAN STANDARD is: 2% lidocaine with 1:100,000 epinephrine: 1-5 m L (20-100 mg lidocaine) locally infiltrated; max 7 mg/kg lidocaine (up to 500 mg) per procedure. For nerve block: 1-30 m L depending on site. Epinephrine max 0.2 mg (20 m L of 1:100,000 solution) in healthy adults.. The standard adult dose of ISOCAINE HYDROCHLORIDE W/ LEVONORDEFRIN is: Adult dental infiltration or nerve block: 1-2 m L of 2% solution (20 mg/m L isocaine hydrochloride with levonordefrin 1:20,000) administered subcutaneously; maximum single dose 5 m L (100 mg isocaine hydrochloride); maximum total dose 7 m L per appointment.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between LIGNOSPAN STANDARD and ISOCAINE HYDROCHLORIDE W/ LEVONORDEFRIN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. LIGNOSPAN STANDARD is classified as Category C. Lignospan standard contains lidocaine and epinephrine. Lidocaine crosses the placenta and is classified as FDA pregnancy category B; no evidence of teratogenicity in animal studies. ISOCAINE HYDROCHLORIDE W/ LEVONORDEFRIN is classified as Category C. In the first trimester, no well-controlled studies in humans; animal studies insufficient. In second and third trimesters, lidocaine (component) crosses placenta with fetal serum l. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.